Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia

Posted by rob on August 27, 2009 under Uncategorized | Comments are off for this article

Conclusion: This is the first report of development of LSetA, a sclerosing dermatosis, while receiving a therapeutic dose of imatinib mesylate, a drug thought to have anti-sclerotic properties. Skupsky H, Abuav R, High W, Pass C, Goldenberg G. Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia. (Source: Journal of Cutaneous Pathology)
More